Comprehensive drug policies that leave no one affected by the world drug problem behind

At its regular 66th session in March 2023, the CND decided on the modalities for the 2024 midterm review of progress made in the implementation of the international drug policy commitments. The Commission will convene a 2-day high-level segment, which consists of a general debate and two interactive multi-stakeholder round-table discussions. At the opening of the high-level segment, the Commission is expected to adopt a concise and action-oriented outcome document.

Safe handling and disposal of synthetic drugs, their precursors and other chemicals used in the illicit manufacture of drugs; Strengthening information sharing to increase scientific evidence-based support to international scheduling and the effective implementation of international scheduling decisions; and Promoting alternative development as a development-oriented drug control strategy that is sustainable and inclusive.

At its regular 66th session, the Commission committed, inter alia, to:

- **Scheduling**
  - The Commission exercises its normative function entitled “scheduling”, under which it decides on the scope of control of substances under the international drug control conventions of 1961, 1971 and 1988. At its regular 66th session, the Commission placed 7 new substances under international control, on the basis of the recommendations of the World Health Organization.

- **Enhancing multi-stakeholder partnerships**
  - In implementing the 2030 Agenda, the Commission actively cooperates with other functional commissions of the Economic and Social Council and works closely with the relevant United Nations entities.

- **Enhanced inclusiveness through digital transformation**
  - With the increased use of digital tools, the Commission has further expanded the possibilities for inclusive and meaningful participation of civil society in its deliberations.